FDA sends a disciplinary letter to Biogen for unsubstantiated claims. Maybe someday they'll require evidence that MS progression and gray matter loss in people-not EAE in mice- is changed by these drugs.


FDA rebukes Biogen for misleading over Copaxone competitor
www.globes.co.il
The FDA says Biogen presents unsubstantiated superiority claims that Avonex is better than Copaxone and other multiple sclerosis drugs.